Fluorescence Imaging in Hepatobiliary Surgery

Not Applicable

Withdrawn

• Conditions: Hepatobiliary Surgery

• Registration Number: NCT03946761
• Lead Sponsor: Washington University School of Medicine

Brief Summary

A current gap in the use indocyanine green fluorescence to isolate the biliary system is the dosing amount necessary to fluoresce the biliary system without "over" fluorescing the liver and gallbladder. Over fluorescing surrounding structures such as the liver and gallbladder saturates the image and makes it impossible to identify biliary leaks or differentiate branches of the common bile duct using fluorescent imaging devices. The over dosing does not affect the standard of care procedure, but eliminates the added benefit of the fluorescent imaging technology. The use of "microdoses" (approximately 0.1 mg) of indocyanine green has been trialed and shown promise in some patients. This study aims to do an in depth study utilizing the Cancer goggle systems fluorescent imaging system to determine the correct dose needed to isolate the biliary system without over fluorescing surrounding structures. This dosing study could additionally serve as a pilot study for follow on research using indocyanine green and fluorescent imaging in hepatobiliary surgery.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2019-04-30
• Study First Submitted QC: 2019-05-08
• Study First Posted: 2019-05-13
• Study Start: 2021-12-31
• Status Verified: 2022-01
• Last Update Submitted: 2022-01-06
• Last Update Posted: 2022-01-24
• Primary Completion: 2022-12-31
• Study Completion: 2022-12-31

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Planned open liver resection or ablation.
• At least 18 years of age.
• Able to understand and willing to sign a written informed consent document.

Exclusion Criteria

-History of allergic reactions attributed to ICG, iodine, iodine dye, or other agents used in the study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
The minimum dose of the ICG that causes initial fluorescence of the liver	Through completion of surgery for all participants enrolled (estimated to take 1 year)

Secondary Outcome Measures

Name	Time	Method
The visible status of the bile ducts and/or bile leaks from the cut surface of the liver at ICG doses administered in our dosing regimen	Through completion of surgery for all participants enrolled (estimated to take 1 year)